PortfoliosLab logo
GlaxoSmithKline plc (GSK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US37733W1053

CUSIP

37733W105

IPO Date

Jul 9, 1986

Highlights

Market Cap

$75.93B

EPS (TTM)

$1.65

PE Ratio

22.73

PEG Ratio

0.36

Total Revenue (TTM)

$24.01B

Gross Profit (TTM)

$16.98B

EBITDA (TTM)

$5.14B

Year Range

$31.37 - $44.37

Target Price

$41.72

Short %

0.80%

Short Ratio

3.35

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in GlaxoSmithKline plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


1,800.00%2,000.00%2,200.00%2,400.00%NovemberDecember2025FebruaryMarchApril
2,069.98%
2,175.43%
GSK (GlaxoSmithKline plc)
Benchmark (^GSPC)

Returns By Period

GlaxoSmithKline plc had a return of 11.89% year-to-date (YTD) and -4.78% in the last 12 months. Over the past 10 years, GlaxoSmithKline plc had an annualized return of 2.53%, while the S&P 500 had an annualized return of 10.11%, indicating that GlaxoSmithKline plc did not perform as well as the benchmark.


GSK

YTD

11.89%

1M

-2.30%

6M

2.01%

1Y

-4.78%

5Y*

1.57%

10Y*

2.53%

^GSPC (Benchmark)

YTD

-6.06%

1M

-3.27%

6M

-4.87%

1Y

9.44%

5Y*

14.30%

10Y*

10.11%

*Annualized

Monthly Returns

The table below presents the monthly returns of GSK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
20254.29%7.75%3.06%-3.38%11.89%
20246.42%7.28%2.32%-3.34%8.93%-14.00%0.70%14.32%-6.90%-10.08%-6.09%-0.91%-5.14%
20230.34%-1.87%3.82%1.26%-5.84%6.07%-0.20%-0.21%3.19%-1.52%1.82%2.97%9.71%
20221.63%-5.26%4.06%3.95%-2.28%-0.84%-4.84%-22.10%-9.39%12.71%5.30%1.59%-18.27%
20211.22%-8.20%6.19%4.62%5.22%2.71%0.80%2.76%-6.21%10.78%-1.67%7.25%26.63%
2020-0.40%-12.21%-6.51%11.03%0.74%-2.70%-1.15%-0.65%-4.95%-11.21%11.48%0.03%-17.78%
20192.59%4.44%3.54%-1.58%-4.89%3.57%3.15%1.87%2.65%7.31%0.38%3.32%29.12%
20185.75%-1.54%7.60%2.66%2.35%-0.52%3.18%-1.46%-0.81%-2.76%8.47%-8.74%13.68%
20172.08%6.97%1.64%-2.99%9.39%-2.51%-6.03%0.50%0.92%-10.27%-2.44%1.17%-3.07%
20162.33%-3.41%4.86%5.82%0.01%2.29%3.99%-2.50%-0.76%-7.23%-4.46%1.91%1.97%
20152.95%9.34%-2.68%-0.00%-2.64%-6.13%4.30%-4.54%-6.06%11.99%-4.61%-0.39%-0.36%
2014-3.47%9.97%-4.49%3.63%-1.47%-0.85%-9.55%2.85%-6.37%-1.04%3.48%-7.99%-15.76%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of GSK is 38, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of GSK is 3838
Overall Rank
The Sharpe Ratio Rank of GSK is 4040
Sharpe Ratio Rank
The Sortino Ratio Rank of GSK is 3434
Sortino Ratio Rank
The Omega Ratio Rank of GSK is 3434
Omega Ratio Rank
The Calmar Ratio Rank of GSK is 3939
Calmar Ratio Rank
The Martin Ratio Rank of GSK is 4545
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The chart of Sharpe ratio for GSK, currently valued at -0.21, compared to the broader market-2.00-1.000.001.002.003.00
GSK: -0.21
^GSPC: 0.46
The chart of Sortino ratio for GSK, currently valued at -0.12, compared to the broader market-6.00-4.00-2.000.002.004.00
GSK: -0.12
^GSPC: 0.77
The chart of Omega ratio for GSK, currently valued at 0.99, compared to the broader market0.501.001.502.00
GSK: 0.99
^GSPC: 1.11
The chart of Calmar ratio for GSK, currently valued at -0.19, compared to the broader market0.001.002.003.004.005.00
GSK: -0.19
^GSPC: 0.47
The chart of Martin ratio for GSK, currently valued at -0.34, compared to the broader market-5.000.005.0010.0015.0020.00
GSK: -0.34
^GSPC: 1.94

The current GlaxoSmithKline plc Sharpe ratio is -0.21. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of GlaxoSmithKline plc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2025FebruaryMarchApril
-0.21
0.46
GSK (GlaxoSmithKline plc)
Benchmark (^GSPC)

Dividends

Dividend History

GlaxoSmithKline plc provided a 4.15% dividend yield over the last twelve months, with an annual payout of $1.55 per share.


4.00%5.00%6.00%7.00%$0.00$0.50$1.00$1.50$2.00$2.5020142015201620172018201920202021202220232024
Dividends
Dividend Yield
PeriodTTM20242023202220212020201920182017201620152014
Dividend$1.55$1.56$1.39$1.68$2.21$2.06$2.05$2.16$2.06$2.77$2.45$2.65

Dividend yield

4.15%4.60%3.75%4.78%4.92%5.49%4.28%5.55%5.72%7.06%5.96%6.09%

Monthly Dividends

The table displays the monthly dividend distributions for GlaxoSmithKline plc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025$0.00$0.40$0.00$0.00$0.40
2024$0.00$0.41$0.00$0.00$0.38$0.00$0.00$0.39$0.00$0.00$0.39$0.00$1.56
2023$0.00$0.34$0.00$0.00$0.35$0.00$0.00$0.36$0.00$0.00$0.34$0.00$1.39
2022$0.00$0.62$0.00$0.00$0.35$0.00$0.00$0.39$0.00$0.00$0.32$0.00$1.68
2021$0.00$0.63$0.00$0.00$0.53$0.00$0.00$0.53$0.00$0.00$0.52$0.00$2.21
2020$0.00$0.60$0.00$0.00$0.47$0.00$0.00$0.49$0.00$0.00$0.50$0.00$2.06
2019$0.00$0.60$0.00$0.00$0.50$0.00$0.00$0.46$0.00$0.00$0.49$0.00$2.05
2018$0.00$0.64$0.00$0.00$0.53$0.00$0.00$0.50$0.00$0.00$0.49$0.00$2.16
2017$0.00$0.58$0.00$0.00$0.49$0.00$0.00$0.50$0.00$0.00$0.50$0.00$2.06
2016$0.00$1.25$0.00$0.00$0.55$0.00$0.00$0.50$0.00$0.00$0.46$0.00$2.77
2015$0.00$0.70$0.00$0.00$0.58$0.00$0.00$0.59$0.00$0.00$0.58$0.00$2.45
2014$0.75$0.00$0.00$0.64$0.00$0.00$0.65$0.00$0.00$0.61$0.00$2.65

Dividend Yield & Payout


Dividend Yield
5.0%10.0%15.0%20.0%25.0%
GSK: 4.2%
GlaxoSmithKline plc has a dividend yield of 4.15%, which is quite average when compared to the overall market.
Payout Ratio
200.0%400.0%600.0%800.0%1,000.0%
GSK: 38.2%
GlaxoSmithKline plc has a payout ratio of 38.23%, which is quite average when compared to the overall market. This suggests that GlaxoSmithKline plc strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-30.00%-25.00%-20.00%-15.00%-10.00%-5.00%0.00%NovemberDecember2025FebruaryMarchApril
-15.61%
-10.07%
GSK (GlaxoSmithKline plc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the GlaxoSmithKline plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the GlaxoSmithKline plc was 55.21%, occurring on Aug 13, 1993. Recovery took 765 trading sessions.

The current GlaxoSmithKline plc drawdown is 15.61%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-55.21%Jan 10, 1992404Aug 13, 1993765Aug 22, 19961169
-51.99%Jan 7, 1999889Jul 23, 20021190Apr 16, 20072079
-49.7%Apr 23, 2007474Mar 9, 2009785Apr 18, 20121259
-46.07%Jul 17, 1987282Aug 25, 1988454Jun 13, 1990736
-38.74%Apr 14, 2022114Sep 27, 2022404May 7, 2024518

Volatility

Volatility Chart

The current GlaxoSmithKline plc volatility is 11.15%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


2.00%4.00%6.00%8.00%10.00%12.00%14.00%NovemberDecember2025FebruaryMarchApril
11.15%
14.23%
GSK (GlaxoSmithKline plc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of GlaxoSmithKline plc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how GlaxoSmithKline plc is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio
20.040.060.080.0100.0
GSK: 22.7
The chart displays the Price-to-Earnings (P/E) ratio for GSK, comparing it with other companies in the Drug Manufacturers - General industry. Currently, GSK has a P/E ratio of 22.7. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
2.04.06.08.010.0
GSK: 0.4
The chart shows the Price/Earnings to Growth (PEG) ratio for GSK compared to other companies in the Drug Manufacturers - General industry. GSK currently has a PEG ratio of 0.4. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
2.04.06.08.010.0
GSK: 2.4
This chart shows the Price-to-Sales (P/S) ratio for GSK relative to other companies in the Drug Manufacturers - General industry. Currently, GSK has a P/S ratio of 2.4. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
2.04.06.08.010.0
GSK: 4.2
The chart illustrates the Price-to-Book (P/B) ratio for GSK in comparison with other companies in the Drug Manufacturers - General industry. Currently, GSK has a P/B value of 4.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items